5-(2-hydroxy-2-methylbut-3-ynyl)-3-(1-methyl-2-pyrrolidinyl)pyridine | 179120-73-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(2-hydroxy-2-methylbut-3-ynyl)-3-(1-methyl-2-pyrrolidinyl)pyridine
• 英文别名: 3-Butyn-2-ol, 2-methyl-4-[5-(1-methyl-2-pyrrolidinyl)-3-pyridinyl]-；2-methyl-4-[5-(1-methylpyrrolidin-2-yl)pyridin-3-yl]but-3-yn-2-ol
• CAS: 179120-73-1
• 化学式: C₁₅H₂₀N₂O
• 分子量: 244.337
• InChiKey: IFPUJRNUSSIRNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-hydroxy-2-methylbut-3-ynyl)-3-(1-methyl-2-pyrrolidinyl)pyridine 在 sodium hydride 作用下， 以 甲苯 为溶剂， 以97%的产率得到5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine
  参考文献：
  名称：

  A Practical and Efficient Synthesis of the Selective Neuronal Acetylcholine-Gated Ion Channel Agonist (S)-(−)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Maleate (SIB-1508Y)

  摘要：

  An efficient, high-yielding synthetic procedure for the preparation of the novel neuronal acetylcholine-gated ion channel agonist (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate [(S)-2, SIB-1508Y] is described. The key steps in the process include the lithium bis(trimethylsilyl)amide-mediated acylation of N-vinylpyrrolidinone with ethyl 5-bromonicotinate, a high-yielding sodium borohydride reduction of imine 5, and a new heteroaryl-alkyne cross-coupling protocol for the introduction of the ethyne moiety in (S)-2. The preparation of enantiomerically pure (S)-2 was accomplished via a combination of enantioselective reduction of imine 5 and crystallization of enantiomerically enriched 5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine (7) as the dibenzoyl-L-tartaric acid salt.

  DOI：

  10.1021/jo971572d
• 作为产物：
  描述：

  5-bromomyosmine 在 palladium on activated charcoal sodium tetrahydroborate 、 copper(l) iodide 、 甲酸 、 potassium carbonate 、 三苯基膦 作用下， 以 甲醇 、 乙二醇二甲醚 、 水 为溶剂， 生成 5-(2-hydroxy-2-methylbut-3-ynyl)-3-(1-methyl-2-pyrrolidinyl)pyridine
  参考文献：
  名称：

  （S）-（-）-5-乙炔基-3-（1-甲基-2-吡咯烷基）吡啶马来酸酯（SIB-1508Y）：一种新型抗帕金森病药物，对神经元烟碱乙酰胆碱受体具有选择性。

  摘要：

  DOI：

  10.1021/jm960328w

文献信息

• [EN] PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS<br/>[FR] MODULATEURS A BASE DE PYRIDINE AGISSANT SUR LES RECEPTEURS DE L'ACETYLCHOLINE
  申请人：SIBIA NEUROSCIENCES, INC.

  公开号：WO1996015123A1

  公开（公告）日：1996-05-23

  (EN) In accordance with the present invention, there is provided a class of pyridine compounds of formula (I) which are modulators of acetylcholine receptors. The compounds of the invention displace acetylcholine receptor ligands from their binding sites. Invention compounds may act as agonists, partial agonists, antagonists or allosteric modulators of acetylcholine receptors, and are useful for a variety of therapeutic applications, such as the treatment of Alzheimer's disease and other disorders involving memory loss and/or dementia (including AIDS dementia); disorders of attention and focus (such as attention deficit disorder); disorders of extrapyramidal motor function such as Parkinson's disease, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, panic, anxiety and psychosis; substance abuse including withdrawal syndromes and substitution therapy; neuroendocrine disorders and dysregulation of food intake, including bulimia and anorexia; disorders of nociception and control of pain; autonomic disorders including dysfunction of gastrointestinal motility and function such as inflammatory bowel disease, irritable bowel syndrome, diarrhea, constipation, gastric acid secretion and ulcers; pheochromocytoma; cardiovascular dysfunction including hypertension and cardia arrhythmias, comedication in surgical procedures, and the like.(FR) L'invention concerne une classe de composés de pyridine de formule (I) qui constituent des modulateurs des récepteurs de l'acétylcholine. Ces composés déplacent les ligands des récepteurs de l'acétylcholine de leurs sites de liaison. Ils peuvent agir comme agonistes, agonistes partiels, antagonistes ou modulateurs allostériques des récepteurs de l'acétylcholine et conviennent à diverses thérapies telles que les traitements de la maladie d'Alzheimer et d'autres troubles impliquant des pertes de mémoire et/ou la démence (y compris celle due au Sida); des troubles de l'attention et de la concentration (tels que le trouble déficitaire de l'attention); des troubles des fonctions motrices extrapyramidales tels que la maladie de Parkinson, la chorée de Huntington, la maladie de Gilles de la Tourette et les dyskinésies tardives; des troubles de l'humeur et des émotions tels que dépression, panique, anxiété et psychose; l'usage de drogues, y compris les syndromes de sevrage, et dans les thérapies de substitution; des troubles neuro-endocriniens et des dérèglements alimentaires, y compris la boulimie et l'anorexie; des troubles de la nociception et ceux dus à la lutte contre la douleur; des troubles du système nerveux autonome, y compris les dysfonctionnements de la motilité et des fonctions intestinaux, tels que maladie intestinale inflammatoire, syndrome du côlon irritable, diarrhée, constipation, troubles de la sécrétion d'acide gastrique et ulcères; du phéochromocytome; des dysfonctionnements cardiovasculaires, y compris l'hypertension et les arythmies cardiaques; des comédications relatives aux procédures chirurgicales, etc.

  根据本发明，提供了一类式为(I)的吡啶化合物，它们是乙酰胆碱受体调节剂。本发明的化合物将乙酰胆碱受体配体从其结合位点上排挤出来。发明的化合物可以作为乙酰胆碱受体的激动剂、部分激动剂、拮抗剂或异构调节剂，并且可用于各种治疗应用，例如治疗阿尔茨海默病和其他涉及记忆丧失和/或痴呆（包括艾滋病痴呆）的疾病；注意力和集中力障碍（如注意缺陷障碍）；运动功能失调疾病，如帕金森病、亨廷顿病、吉尔斯·德·拉·图雷特综合征和迟发性舞蹈症；情绪和情感障碍，如抑郁、恐慌、焦虑和精神病；物质滥用，包括戒断综合征和替代疗法；神经内分泌障碍和食欲调节失调，包括贪食症和厌食症；疼痛感知和控制障碍；自主神经障碍，包括胃肠动力和功能障碍，如炎症性肠病、肠易激综合征、腹泻、便秘、胃酸分泌和溃疡；嗜铬细胞瘤；心血管功能障碍，包括高血压和心律失常；手术过程中的联合用药等。
• PYRIDINE MODULATORS OF ACETYLCHOLINE RECEPTORS
  申请人：SIBIA NEUROSCIENCES, INC.

  公开号：EP0739342A1

  公开（公告）日：1996-10-30
• A Practical and Efficient Synthesis of the Selective Neuronal Acetylcholine-Gated Ion Channel Agonist (<i>S</i>)-(−)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine Maleate (SIB-1508Y)
  作者：Leo S. Bleicher、Nicholas D. P. Cosford、Audrey Herbaut、J. Stuart McCallum、Ian A. McDonald

  DOI：10.1021/jo971572d

  日期：1998.2.1

  An efficient, high-yielding synthetic procedure for the preparation of the novel neuronal acetylcholine-gated ion channel agonist (S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate [(S)-2, SIB-1508Y] is described. The key steps in the process include the lithium bis(trimethylsilyl)amide-mediated acylation of N-vinylpyrrolidinone with ethyl 5-bromonicotinate, a high-yielding sodium borohydride reduction of imine 5, and a new heteroaryl-alkyne cross-coupling protocol for the introduction of the ethyne moiety in (S)-2. The preparation of enantiomerically pure (S)-2 was accomplished via a combination of enantioselective reduction of imine 5 and crystallization of enantiomerically enriched 5-bromo-3-(1-methyl-2-pyrrolidinyl)pyridine (7) as the dibenzoyl-L-tartaric acid salt.
• (<i>S</i>)-(−)-5-Ethynyl-3-(1-methyl-2-pyrroli- dinyl)pyridine Maleate (SIB-1508Y):  A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors
  作者：Nicholas D. P. Cosford、Leo Bleicher、Audrey Herbaut、J. Stuart McCallum、Jean-Michel Vernier、Heather Dawson、Jeffrey P. Whitten、Pamala Adams、Laura Chavez-Noriega、Lucia D. Correa、James H. Crona、Lorrence S. Mahaffy、Frederique Menzaghi、Tadimeti S. Rao、Richard Reid、Aida I. Sacaan、Emily Santori、Kenneth A. Stauderman、Kevin Whelan、G. Kenneth Lloyd、Ian A. McDonald

  DOI：10.1021/jm960328w

  日期：1996.1.1